Feasibility And Safety Study Of rhBMP-2/CPM For Hip Fractures

NCT ID: NCT00384358

Last Updated: 2013-02-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

108 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-12-31

Study Completion Date

2010-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of this study is to assess the safety of administering rhBMP-2/CPM as an adjuvant to internal fixation in subjects with fractures of the proximal femur.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Fractures

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

A

1.0 mg/mL rhBMP-2/CPM + surgical fixation

Group Type EXPERIMENTAL

rhBMP-2/CPM

Intervention Type DRUG

one time injection of 3-5 mL test article at time of internal fracture fixation

B

2.0 mg/mL rhBMP-2/CPM + surgical fixation

Group Type EXPERIMENTAL

rhBMP-2/CPM

Intervention Type DRUG

one time injection of 3-5 mL test article at time of internal fracture fixation

C

Control: Surgical fixation

Group Type OTHER

surgical intervention alone

Intervention Type OTHER

surgical internal fixation of fracture defines the standard of care group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

rhBMP-2/CPM

one time injection of 3-5 mL test article at time of internal fracture fixation

Intervention Type DRUG

rhBMP-2/CPM

one time injection of 3-5 mL test article at time of internal fracture fixation

Intervention Type DRUG

surgical intervention alone

surgical internal fixation of fracture defines the standard of care group

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 55 or older.
* Acute fracture of the proximal femur: displaced femoral neck fracture or unstable intertrochanteric femur fracture.
* Anatomic reduction (open or closed) and internal fixation within 48 hours following injury using any one of the following fixation constructs: 1) multiple parallel interfragmentary screws; 2) sliding hip screw and side plate fixation; or 3) cephalomedullary nail.

Exclusion Criteria

* Concurrent fractures of the ipsilateral or contralateral lower extremity that would impede performance on functional assessments.
* Previous arthroplasty of contralateral (unaffected) hip.
* Planned procedure(s) to stimulate fracture healing after internal fixation of the fractured hip.
Minimum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pfizer CT.gov Call Center

Role: STUDY_DIRECTOR

Pfizer

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Pfizer Investigational Site

Aurora, Colorado, United States

Site Status

Pfizer Investigational Site

New Haven, Connecticut, United States

Site Status

Pfizer Investigational Site

Clearwater, Florida, United States

Site Status

Pfizer Investigational Site

Pinellas Park, Florida, United States

Site Status

Pfizer Investigational Site

Decatur, Georgia, United States

Site Status

Pfizer Investigational Site

New Brunswick, New Jersey, United States

Site Status

Pfizer Investigational Site

Brooklyn, New York, United States

Site Status

Pfizer Investigational Site

Elmhurst, New York, United States

Site Status

Pfizer Investigational Site

Liverpool, New South Wales, Australia

Site Status

Pfizer Investigational Site

Herston, Queensland, Australia

Site Status

Pfizer Investigational Site

Adelaide, South Australia, Australia

Site Status

Pfizer Investigational Site

Melbourne, Victoria, Australia

Site Status

Pfizer Investigational Site

Parkville, Victoria, Australia

Site Status

Pfizer Investigational Site

Ajax, Ontario, Canada

Site Status

Pfizer Investigational Site

Chatham, Ontario, Canada

Site Status

Pfizer Investigational Site

Scarborough Village, Ontario, Canada

Site Status

Pfizer Investigational Site

Montreal, Quebec, Canada

Site Status

Pfizer Investigational Site

Oulu, , Finland

Site Status

Pfizer Investigational Site

Turku, , Finland

Site Status

Pfizer Investigational Site

Créteil, , France

Site Status

Pfizer Investigational Site

Marseille, , France

Site Status

Pfizer Investigational Site

Berlin, , Germany

Site Status

Pfizer Investigational Site

Münster, , Germany

Site Status

Pfizer Investigational Site

Budapest, , Hungary

Site Status

Pfizer Investigational Site

Debrecen, , Hungary

Site Status

Pfizer Investigational Site

Bergen, , Norway

Site Status

Pfizer Investigational Site

Oslo, , Norway

Site Status

Pfizer Investigational Site

Link?ping, , Sweden

Site Status

Pfizer Investigational Site

Edinburgh, , United Kingdom

Site Status

Pfizer Investigational Site

Norwich, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Australia Canada Finland France Germany Hungary Norway Sweden United Kingdom

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

B1921004

Identifier Type: -

Identifier Source: secondary_id

3100N7-211

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

POLARSTEM Cementless Hip Stem
NCT02648152 COMPLETED